Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GMAB NASDAQ:SMMT NASDAQ:ZLAB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGMABGenmab A/S$27.06-3.0%$27.32$18.89▼$35.43$17.39B0.861.57 million shs3.50 million shsSMMTSummit Therapeutics$17.15-3.9%$18.52$13.83▼$30.98$13.85B-1.255.20 million shs2.72 million shsZLABZai Lab$19.76-5.9%$20.23$15.96▼$44.34$2.38B0.85772,841 shs1.27 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGMABGenmab A/S-2.98%+2.04%-2.13%-12.43%+30.80%SMMTSummit Therapeutics-3.92%-20.08%-10.77%+14.41%-29.26%ZLABZai Lab-5.95%-8.69%-5.90%+9.78%-30.32%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGMABGenmab A/S$27.06-3.0%$27.32$18.89▼$35.43$17.39B0.861.57 million shs3.50 million shsSMMTSummit Therapeutics$17.15-3.9%$18.52$13.83▼$30.98$13.85B-1.255.20 million shs2.72 million shsZLABZai Lab$19.76-5.9%$20.23$15.96▼$44.34$2.38B0.85772,841 shs1.27 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGMABGenmab A/S-2.98%+2.04%-2.13%-12.43%+30.80%SMMTSummit Therapeutics-3.92%-20.08%-10.77%+14.41%-29.26%ZLABZai Lab-5.95%-8.69%-5.90%+9.78%-30.32%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGMABGenmab A/S 2.92Moderate Buy$39.0744.39% UpsideSMMTSummit Therapeutics 2.50Moderate Buy$27.5860.84% UpsideZLABZai Lab 2.63Moderate Buy$50.00153.04% UpsideCurrent Analyst Ratings BreakdownLatest ZLAB, SMMT, and GMAB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/4/2026SMMTSummit Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$30.00 ➝ $23.005/1/2026SMMTSummit Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$17.00 ➝ $16.004/30/2026GMABGenmab A/S HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$40.00 ➝ $38.004/27/2026GMABGenmab A/S Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/24/2026ZLABZai Lab Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/22/2026GMABGenmab A/S BNP Paribas ExaneSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy4/22/2026GMABGenmab A/S The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy4/21/2026SMMTSummit Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/8/2026SMMTSummit Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy4/8/2026SMMTSummit Therapeutics Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$45.003/27/2026GMABGenmab A/S Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$32.00(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGMABGenmab A/S$3.72B4.54$1.56 per share17.33$9.10 per share2.97SMMTSummit TherapeuticsN/AN/AN/AN/A$0.70 per shareN/AZLABZai Lab$453.28M4.94N/AN/A$6.39 per share3.09Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGMABGenmab A/S$963M$1.5517.4616.201.2425.89%17.35%11.69%N/ASMMTSummit Therapeutics-$1.08B-$1.60N/AN/AN/AN/A-291.24%-243.07%N/AZLABZai Lab-$175.54M-$1.61N/AN/AN/A-38.15%-22.81%-15.04%N/ALatest ZLAB, SMMT, and GMAB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026ZLABZai Lab-$0.5262-$0.46+$0.0662-$0.50$108.43 million$99.61 million4/30/2026Q1 2026SMMTSummit Therapeutics-$0.2692-$0.24+$0.0292-$0.24$0.05 millionN/A4/1/2026Q1 2026ZLABZai LabN/A-$0.50N/A-$0.50N/A$99.61 million2/26/2026Q4 2025ZLABZai Lab-$0.44-$0.46-$0.02-$0.50$122.67 million$127.60 million2/23/2026Q4 2025SMMTSummit Therapeutics-$0.22-$0.29-$0.07-$0.29$75.47 millionN/A2/18/2026Q4 2025GMABGenmab A/S$0.46$0.05-$0.41$0.0470$1.06 billion$1.06 billion2/14/2026Q4 2025ZLABZai LabN/A-$0.50N/A-$0.50N/A$127.60 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthGMABGenmab A/SN/AN/AN/AN/AN/ASMMTSummit TherapeuticsN/AN/AN/AN/AN/AZLABZai LabN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGMABGenmab A/S0.862.022.01SMMTSummit TherapeuticsN/A7.419.87ZLABZai LabN/A2.452.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGMABGenmab A/S7.07%SMMTSummit Therapeutics4.61%ZLABZai Lab41.65%Insider OwnershipCompanyInsider OwnershipGMABGenmab A/S1.54%SMMTSummit Therapeutics83.50%ZLABZai Lab4.96%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGMABGenmab A/S3,029623.51 million613.91 millionOptionableSMMTSummit Therapeutics110776.16 million128.07 millionOptionableZLABZai Lab1,784113.41 million107.79 millionOptionableZLAB, SMMT, and GMAB HeadlinesRecent News About These CompaniesZai Lab Limited (ZLAB) Q1 2026 Earnings Call TranscriptMay 7 at 11:00 PM | seekingalpha.comZai Lab (NASDAQ:ZLAB) Issues Quarterly Earnings ResultsMay 7 at 10:49 PM | marketbeat.comZai Lab Limited (ZLAB) Reports Q1 Earnings: What Key Metrics Have to SayMay 7 at 10:31 AM | zacks.comZai Lab Announces First Quarter 2026 Financial Results and Recent Corporate UpdatesMay 7 at 7:24 AM | finance.yahoo.comZai Lab (ZLAB) Expected to Announce Earnings on ThursdayApril 30, 2026 | marketbeat.comAssessing Zai Lab (ZLAB) Valuation After Recent Share Price Momentum And Analyst Target ResetApril 29, 2026 | finance.yahoo.comZai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesApril 26, 2026 | marketbeat.comZai Lab Showcases 54% Brain Metastases Response for ZL-1310 ADC in SCLC at AACR Investor CallApril 26, 2026 | marketbeat.comZai Lab Limited (ZLAB) Discusses Intracranial Activity of a New Therapy in Small Cell Lung Cancer With Brain Metastases - SlideshowApril 22, 2026 | seekingalpha.comZai Lab (NASDAQ:ZLAB) Trading Down 5.2% - Here's What HappenedApril 22, 2026 | marketbeat.comZai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026April 22, 2026 | businesswire.comZai Lab Limited (ZLAB) Discusses Intracranial Activity of a New Therapy in Small Cell Lung Cancer With Brain Metastases TranscriptApril 20, 2026 | seekingalpha.comZai Lab Presents New Preclinical Data Suggesting ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, Provides Rapid Itch Relief and Reduction in Inflammation in Atopic DiseasesApril 18, 2026 | businesswire.comZai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and ...April 18, 2026 | finance.yahoo.comZai Lab stock rises on positive trial data for cancer drugApril 18, 2026 | in.investing.comZai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine CarcinomasApril 17, 2026 | businesswire.comZai Lab (NASDAQ:ZLAB) Sees Unusually-High Trading Volume - Time to Buy?April 17, 2026 | marketbeat.comZai Lab Limited - Depositary Receipt (ZLAB) price target increased by 19.30% to 26.69April 15, 2026 | msn.comBoehringer Ingelheim and Zai Lab announce Collaboration on DLL3‑targeting T‑Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine CarcinomasApril 15, 2026 | globenewswire.comZai Lab Ltd. Sponsored ADRApril 10, 2026 | edition.cnn.comInsider Selling: Zai Lab (NASDAQ:ZLAB) CFO Sells 853 Shares of StockApril 9, 2026 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeZLAB, SMMT, and GMAB Company DescriptionsGenmab A/S NASDAQ:GMAB$27.06 -0.83 (-2.98%) Closing price 05/7/2026 04:00 PM EasternExtended Trading$24.86 -2.20 (-8.12%) As of 05:22 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.Summit Therapeutics NASDAQ:SMMT$17.15 -0.70 (-3.92%) Closing price 05/7/2026 04:00 PM EasternExtended Trading$17.32 +0.18 (+1.02%) As of 05:24 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.Zai Lab NASDAQ:ZLAB$19.76 -1.25 (-5.95%) Closing price 05/7/2026 04:00 PM EasternExtended Trading$19.41 -0.35 (-1.77%) As of 05:18 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally IonQ Just Posted a Breakout Quarter—But 1 Problem Remains Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Nuts and Bolts AI Play Gains Momentum: Astera Labs Targets Raised Anheuser-Busch Stock Jumps as Volume Growth Signals Turnaround Light Speed Returns: Corning Cashes In on NVIDIA Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
